Actively Recruiting
Phase 2 Study Comparing Topical MW-III and Silvadene Cream for Healing Partial Thickness Thermal Burns
Led by Skingenix, Inc. · Updated on 2026-03-16
60
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of a topical drug called MW-III for treating thermal burns in adults. The study compares MW-III to Silvadene4 Cream 1% Silver Sulfadiazine to see which one helps burns heal faster. This is a phase 2 pilot study focused on partial thickness burns and aims to measure the time it takes for burns to reach at least 95% skin healing. Participants will be randomly assigned to receive either MW-III or Silvadene4 Cream applied topically twice a day. The treatment period lasts 28 days, during which the progress of the burn healing will be closely monitored. The study groups include an experimental group using MW-III and an active comparator group using the standard Silvadene4 treatment. During the study, participants will have regular assessments to track healing progress, including measuring the time to 95% re-epithelialization of the burn area. Researchers will also evaluate the proportion of burns healed at scheduled visits, the need for skin grafting, and scar appearance using a scar scoring system. Participants will be monitored throughout the 28-day treatment period to assess safety and treatment effects.
CONDITIONS
Brief Title
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Research Team
V
Vicki Christodoulou, MS, JD
E
Eric Wang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
